scispace - formally typeset
Search or ask a question
Author

Wellerson de Oliveira Carneiro Junior

Bio: Wellerson de Oliveira Carneiro Junior is an academic researcher from Universidade Federal de Minas Gerais. The author has contributed to research in topics: Neuroprotection & Neurodegeneration. The author has an hindex of 2, co-authored 2 publications receiving 35 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: Compound 4c showed a similar binding mode to donepezil in both acetylated and free forms of AChE enzyme in molecular docking studies and did not show relevant toxic effects on in vitro and in-vivo assays, with good predicted ADME parameters in silico.

39 citations

Journal ArticleDOI
TL;DR: Despite a four-week treatment did not prevent memory loss in aged transgenic mice, CDPPB possess is protective against Aβ stimulus, therefore, this drug represents a potential candidate for further investigations as AD treatment.

17 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: After many years from the introduction in therapy of ChE-Is, the combination with other classes of drugs may represent the chance for a renewed interest of Ch E-Is in the treatment of adult-onset dementia disorders.

252 citations

Journal ArticleDOI
TL;DR: Concerns and opinions about development of donepezil derivatives, designing of MTDLs, and perspectives for AD treatments are discussed in final part.

119 citations

Journal ArticleDOI
TL;DR: The most recent advances of the exploitation of Molecular Hybridization (MH) as a tool in the rational design of innovative multifunctional drug candidate prototypes for the treatment of NDs, specially focused on AD, PD, HD and ALS are highlighted.
Abstract: Neurodegenerative Diseases (NDs) are progressive multifactorial neurological pathologies related to neuronal impairment and functional loss from different brain regions. Currently, no effective treatments are available for any NDs, and this lack of efficacy has been attributed to the multitude of interconnected factors involved in their pathophysiology. In the last two decades, a new approach for the rational design of new drug candidates, also called multitarget-directed ligands (MTDLs) strategy, has emerged and has been used in the design and for the development of a variety of hybrid compounds capable to act simultaneously in diverse biological targets. Based on the polypharmacology concept, this new paradigm has been thought as a more secure and effective way for modulating concomitantly two or more biochemical pathways responsible for the onset and progress of NDs, trying to overcome low therapeutical effectiveness. As a complement to our previous review article (Curr. Med. Chem. 2007, 14 (17), 1829-1852. https://doi.org/10.2174/092986707781058805), herein we aimed to cover the period from 2008 to 2019 and highlight the most recent advances of the exploitation of Molecular Hybridization (MH) as a tool in the rational design of innovative multifunctional drug candidate prototypes for the treatment of NDs, specially focused on AD, PD, HD and ALS.

52 citations

Journal ArticleDOI
TL;DR: A revision of the literature and a review based on some of the most current research reports of hydrazones and derivatives are performed, making it clear that the synthesis of these molecules can lead to new drug prototypes.
Abstract: Hydrazones and their derivatives are very important compounds in medicinal chemistry due to their reported biological activity for the treatment of several diseases, like Alzheimer's, cancer, inflammation, and leishmaniasis. However, most of the investigations on hydrazones available in literature today are directed to the synthesis of these molecules with little discussion available on their biological activities. With the purpose of bringing lights into this issue, we performed a revision of the literature and wrote this review based on some of the most current research reports of hydrazones and derivatives, making it clear that the synthesis of these molecules can lead to new drug prototypes. Our goal is to encourage more studies focused on the synthesis and evaluation of new hydrazones, as a contribution to the development of potential new drugs for the treatment of various diseases.

48 citations

Journal ArticleDOI
TL;DR: The progress made over the last 5 years on the development of MTDLs inspired by drugs approved for AD are revised to rationalize the large amount of data obtained.

42 citations